Gemini CEO out the door as 80% of staff laid off, strategic review gets underway

Gemini season came quite early for a biotech of the same name. The CEO of Gemini Therapeutics exited Monday as the company laid off 80% of its staff, shifted priorities to a preclinical asset and began searching for a future.